Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: oldcoach19 who wrote (1352)	6/30/2015 4:12:31 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

Kinda doubt it. That is a level of micromanaging that I hope Denner does not do. And RPRX has not exactly been fattening investors' wallets these days, regardless of its IR efforts. That may change as the FDA considers its hypogonadism drug. I have thought that for a micro biotech having two IR firms was over the top. Collins was great (IMO) for retail investors. But apparently his firm did not have the reach to cover all the needs of Apricus.